These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 25483694

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis.
    Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R, Muenz L, Fuller S, Johnson J, Fireman B, Alcorn H, Naso R.
    N Engl J Med; 2002 Feb 14; 346(7):491-6. PubMed ID: 11844850
    [Abstract] [Full Text] [Related]

  • 3. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients.
    Fattom A, Fuller S, Propst M, Winston S, Muenz L, He D, Naso R, Horwith G.
    Vaccine; 2004 Dec 16; 23(5):656-63. PubMed ID: 15542186
    [Abstract] [Full Text] [Related]

  • 4. Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial.
    Creech CB, Frenck RW, Sheldon EA, Seiden DJ, Kankam MK, Zito ET, Girgenti D, Severs JM, Immermann FW, McNeil LK, Cooper D, Jansen KU, Gruber W, Eiden J, Anderson AS, Baber J.
    Vaccine; 2017 Jan 05; 35(2):385-394. PubMed ID: 27866765
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial.
    Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW, Corey GR, Carmeli Y, Betts R, Hartzel JS, Chan IS, McNeely TB, Kartsonis NA, Guris D, Onorato MT, Smugar SS, DiNubile MJ, Sobanjo-ter Meulen A.
    JAMA; 2013 Apr 03; 309(13):1368-78. PubMed ID: 23549582
    [Abstract] [Full Text] [Related]

  • 7. Phase IIa study of the immunogenicity and safety of the novel Staphylococcus aureus vaccine V710 in adults with end-stage renal disease receiving hemodialysis.
    Moustafa M, Aronoff GR, Chandran C, Hartzel JS, Smugar SS, Galphin CM, Mailloux LU, Brown E, Dinubile MJ, Kartsonis NA, Guris D.
    Clin Vaccine Immunol; 2012 Sep 03; 19(9):1509-16. PubMed ID: 22837094
    [Abstract] [Full Text] [Related]

  • 8. Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study.
    Frenck RW, Creech CB, Sheldon EA, Seiden DJ, Kankam MK, Baber J, Zito E, Hubler R, Eiden J, Severs JM, Sebastian S, Nanra J, Jansen KU, Gruber WC, Anderson AS, Girgenti D.
    Vaccine; 2017 Jan 05; 35(2):375-384. PubMed ID: 27916408
    [Abstract] [Full Text] [Related]

  • 9. A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults.
    Nissen M, Marshall H, Richmond P, Shakib S, Jiang Q, Cooper D, Rill D, Baber J, Eiden J, Gruber W, Jansen KU, Emini EA, Anderson AS, Zito ET, Girgenti D.
    Vaccine; 2015 Apr 08; 33(15):1846-54. PubMed ID: 25707693
    [Abstract] [Full Text] [Related]

  • 10. SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies.
    Begier E, Seiden DJ, Patton M, Zito E, Severs J, Cooper D, Eiden J, Gruber WC, Jansen KU, Anderson AS, Gurtman A.
    Vaccine; 2017 Feb 22; 35(8):1132-1139. PubMed ID: 28143674
    [Abstract] [Full Text] [Related]

  • 11. Staphylococcus aureus vaccine conjugate--Nabi: Nabi-StaphVAX, StaphVAX.
    Drugs R D; 2003 Feb 22; 4(6):383-5. PubMed ID: 14584973
    [Abstract] [Full Text] [Related]

  • 12. Safety and immunogenicity of a recombinant Staphylococcus aureus α-toxoid and a recombinant Panton-Valentine leukocidin subunit, in healthy adults.
    Landrum ML, Lalani T, Niknian M, Maguire JD, Hospenthal DR, Fattom A, Taylor K, Fraser J, Wilkins K, Ellis MW, Kessler PD, Fahim RE, Tribble DR.
    Hum Vaccin Immunother; 2017 Apr 03; 13(4):791-801. PubMed ID: 28010246
    [Abstract] [Full Text] [Related]

  • 13. Preclinical Efficacy of Clumping Factor A in Prevention of Staphylococcus aureus Infection.
    Li X, Wang X, Thompson CD, Park S, Park WB, Lee JC.
    mBio; 2016 Feb 02; 7(1):e02232-15. PubMed ID: 26838725
    [Abstract] [Full Text] [Related]

  • 14. Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study.
    Marshall H, Nissen M, Richmond P, Shakib S, Jiang Q, Cooper D, Rill D, Baber J, Eiden J, Gruber WC, Jansen KU, Anderson AS, Zito ET, Girgenti D.
    J Infect; 2016 Nov 02; 73(5):437-454. PubMed ID: 27519620
    [Abstract] [Full Text] [Related]

  • 15. Preclinical laboratory evaluation of a bivalent Staphylococcus aureus saccharide-exotoxin A protein conjugate vaccine.
    Ho MM, Bolgiano B, Martino A, Kairo SK, Corbel MJ.
    Hum Vaccin; 2006 Nov 02; 2(3):89-98. PubMed ID: 17012902
    [Abstract] [Full Text] [Related]

  • 16. Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans.
    Harro C, Betts R, Orenstein W, Kwak EJ, Greenberg HE, Onorato MT, Hartzel J, Lipka J, DiNubile MJ, Kartsonis N.
    Clin Vaccine Immunol; 2010 Dec 02; 17(12):1868-74. PubMed ID: 20943877
    [Abstract] [Full Text] [Related]

  • 17. Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines.
    Robbins JB, Schneerson R, Horwith G, Naso R, Fattom A.
    Am Heart J; 2004 Apr 02; 147(4):593-8. PubMed ID: 15077073
    [Abstract] [Full Text] [Related]

  • 18. S. aureus colonization in healthy Australian adults receiving an investigational S. aureus 3-antigen vaccine.
    Marshall HS, Baber J, Richmond P, Nissen M, Shakib S, Kreiswirth BN, Zito ET, Severs J, Eiden J, Gruber W, Jansen KU, Jones CH, Anderson AS.
    J Infect; 2019 Dec 02; 79(6):582-592. PubMed ID: 31585191
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection.
    Cheng BL, Nielsen TB, Pantapalangkoor P, Zhao F, Lee JC, Montgomery CP, Luna B, Spellberg B, Daum RS.
    Hum Vaccin Immunother; 2017 Jul 03; 13(7):1609-1614. PubMed ID: 28422567
    [Abstract] [Full Text] [Related]

  • 20. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia.
    Rupp ME, Holley HP, Lutz J, Dicpinigaitis PV, Woods CW, Levine DP, Veney N, Fowler VG.
    Antimicrob Agents Chemother; 2007 Dec 03; 51(12):4249-54. PubMed ID: 17893153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.